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Multiple observational cohorts describing the outcome of patients with COVID-19 
from across the world have been published.1-3 Typically, these have reported 
regional or national cohorts and no two countries have had the same experience. 
The reasons for this are complex and difficult to quantify. Nonetheless, to be able to 
draw meaningful inferences from these data we must tackle the issues associated 
with international comparison.  
 
Initial reports of outcomes in COVID-19, which emerged from China early in the 
pandemic, reported a range of ICU mortality (0-78%).3 Case series from North 
America and Europe have been equally variable (ICU mortality 0-85%).3 A major 
issue has been the large number of patients in these series who had incomplete 
outcomes at the time of reporting, a factor which has commonly resulted in mortality 
being over- or underestimated. An example of this can be found in the UK Intensive 
Care National Audit and Research Centre (ICNARC) data. Early reports from March 
estimated ICU mortality to be 48%, when 79% of 775 patients had an incomplete 
outcome. In the latest report, from 31st July 2020, ICU mortality had fallen to 40% in 
10,341 patients with complete outcomes.4 Table 1 summarises current European 
data on COVID-19 mortality, highlighting the range of outcome measures reported. 
Another key difference is the status of the health systems in which these patients 
have been managed, in particular the degree of ‘stress’ which those systems were 
under.5 This is more difficult to adjust for. Variations in clinical decision-making 
between healthcare systems, reflected in the characteristics of patients admitted to 
ICUs and in the modes of ventilation employed, also confound direct comparison. 
This is potentially evident when comparing ICU admissions between the UK and 
Germany, where the median age of patients receiving invasive mechanical 
ventilation was 72 years in a large German series2 versus 60 years in the latest 
ICNARC report.4 However, ICU mortality was similar, emphasising the role of 
admission criteria. Regardless, the wide variation observed suggests the possibility 
that some factors are modifiable. Therefore, it is important that we can make 
comparisons between countries and systems.   
 
Beyond careful epidemiological analysis, there are several ways in which we may 
improve comparisons. The most obvious is multinational collaboration. Indeed, it is 
difficult to see how we can mount an effective response to a global pandemic without 
it. The fight against COVID-19 has already produced some commendable examples, 
including the work of the Coalition for Preparedness Innovations (CEPI), of the 
Global Alliance for Vaccines and Immunizations (GAVI), and the of the International 
Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). However, 
global comparative data on the outcomes from COVID-19 are lacking as a single 
observational study has not been reported to date. An issue with the current reports 
is the inconsistency of the hospital, ICU and individual patient level data definitions. 
Similarly, there are often fundamental differences in the design of these studies. 
Together these limitations make linkage or comparison difficult, which limits our 
ability to generate sufficiently robust data to form conclusions. While a single global 
study may be logistically and politically improbable, there are simpler measures 
which may ease the task of generating international data with fewer limitations. 
 
First, the development of harmonised case report forms and data dictionaries would 
permit straightforward comparison of studies. This approach would also allow 
investigators to create tiers of data collection. This is of real importance in resource 
limited settings, in which the advanced monitoring, diagnostics, and research 
infrastructure required to perform extensive study protocols are not available. The 
use of core outcomes in ICU observational studies should also be addressed, for 
example the WHO Working Group on the Clinical Characterisation and Management 
of COVID-19 Infection outcome set.6 Second, the inclusion of measures of system 
stress and resource availability have been largely missing from published studies to 
date. These are essential to understand the observational data collected in the midst 
of a pandemic. For example, evidence of national variation in ICU outcome has been 
described during the first wave of the COVID-19 pandemic in England.7 Here, the 
authors hypothesised that this may have occurred as the result of local strain or 
resource-constraints in the face of a surge. Likewise, a recent study from Brazil has 
highlighted disparities in the outcomes of hospitalised patients between the south of 
the country and the economically poorer north.8 In practice this may mean collecting 
hospital and unit level information on resource availability and staffing over time, in 
addition to patient-level data. Third, integrating ICU observational studies with those 
that capture patients before and after admission to critical care, as well as linkage to 
clinical trial data, would be advantageous. This would better characterise patients 
and would reduce the replication of data collection. Another benefit would be the 
ability to assess the influence of variations in clinical decision-making on ICU 
outcome, which hinder the comparison of existing studies. Furthermore, the effective 
linkage of large observational studies and clinical trials would allow investigators to 
better explore sub-group effects and identify heterogeneity of treatment effect, such 
as was identified in the RECOVERY dexamethasone study.9      
 
Current reports of ICU outcome for patients with COVID-19 vary between countries. 
The reasons for this are unknown but are unlikely to be attributable to differences in 
the virus or host-response alone. Understanding those that are modifiable would be 
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patient 
inclusion 





















Belgium June 14 16,628* 53% male/ 
median 71y* 
21% 1,696* n/a/  
median 
66y 
n/a n/a n/a n/a 




107,010* 53% male/ 
median 72y* 
20% 4,007* 73% 
male/ 
19% >75y 
23% n/a n/a n/a 
Germany April 19 10,021** 52% male/ 
median 72y** 
22% n/a n/a n/a 1,727** 66% male/ 
median 71y** 
53%## 





n/a n/a n/a 
UK: England, 
Scotland, Wales 
April 19 20,133* 60% male/ 
median 73y* 










7,425* 72% male/ 
median 60y* 
48%# 
* all patients (including those still in hospital); ** dead as % of discharged dead or alive; # in ICU; ## in hospital; + invasive ventilation only 
Table 1. Euorpean mortality outcomes for COVID-19 
Sources 
BE – Sciensano. POINTS CLÉS DE LA SURVEILLANCE DES PATIENTS HOSPITALISÉS ATTEINTS D’UNE INFECTION COVID-19 
CONFIRMÉE https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_THEMATIC%20REPORT_COVID-
19%20HOSPITALISED%20PATIENTS_FR.pdf 
FR – COVID-19 - Point épidémiologique hebdomadaire du 30 julliet 2020 (hospitalisations) 
https://www.santepubliquefrance.fr/content/download/271059/2691560 / COVID-19 - Point épidémiologique hebdomadaire du 4 juin 2020 
(ICU) https://www.santepubliquefrance.fr/content/download/257630/2628879  
NL – https://stichting-nice.nl/covid-19-op-de-zkh.jsp & https://stichting-nice.nl/covid-19-op-de-ic.jsp 
UK - Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: 
prospective observational cohort study. BMJ 2020; 369:m1985. 
Intensive Care National Audit and Research Centre. ICNARC report on COVID-19 in critical care. https://www.icnarc.org/Our-
Audit/Audits/Cmp/Reports. 31/07/2020. 
 
